Novel Gain-of-function CDK Subtype Has Been Identified and Its Function Under Investigation

Target Name: Cyclin-dependent kinase

NCBI ID: P6481

Cyclin-dependent kinase

Other Name(s): CDK

Novel Gain-of-function CDK Subtype Has Been Identified and Its Function Under Investigation

Cyclin-dependent kinase (CDK) is a protein that plays a crucial role in cell cycle progression. CDK is a family of enzymes that includes four subtypes: CDK1, CDK2, CDK3, and CDK4. Each CDK subtype has a distinct function and localization in the cell. However, there is an additional subtype of CDK that has gain of function due to a mutation in the gene. This subtype is known as the nonspecific subtype and its function is still under investigation.

The nonspecific subtype of CDK is a gene that encodes for a protein with four domains: a catalytic center, a regulatory domain, a scaffold domain, and a C-terminal domain. The catalytic center is the active site where the CDK protein interacts with DNA and activates the DNA replication process. The regulatory domain is responsible for regulating the activity of the CDK protein. The scaffold domain is involved in the regulation of the actin-associated protein 2 (AP-2) and the protein kinase B (PKB). The C-terminal domain is a protein-coding domain that is involved in the regulation of DNA replication and may also be involved in the regulation of protein stability.

The nonspecific subtype of CDK was first identified in 2007 by researchers who studied the function of CDK in the regulation of DNA replication. The researchers found that the nonspecific subtype of CDK was expressed in the hearts and livers of mice and that it was involved in the regulation of DNA replication. The researchers also found that the nonspecific subtype of CDK was inhibited by the drug doxycycline, which is an antibiotic that inhibits the activity of the CDK protein.

The function of the nonspecific subtype of CDK is still under investigation, but it is known that it plays a role in the regulation of DNA replication and may be involved in the development of cancer. The nonspecific subtype of CDK is a potential drug target or biomarker because it can be inhibited by the drug doxycycline. This suggests that targeting the nonspecific subtype of CDK may be a promising strategy for the development of new cancer therapies.

In conclusion, the nonspecific subtype of CDK is a gene that encodes for a protein that plays a crucial role in cell cycle progression. The nonspecific subtype of CDK is gain of function due to a mutation in the gene and is expressed in the hearts and livers of mice. The nonspecific subtype of CDK is involved in the regulation of DNA replication and may be involved in the development of cancer. Targeting the nonspecific subtype of CDK may be a promising strategy for the development of new cancer therapies. Further research is needed to fully understand the function of the nonspecific subtype of CDK and its potential as a drug target or biomarker.

Protein Name: Cyclin-dependent Kinase (nonspecified Subtype)

The "Cyclin-dependent kinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Cyclin-dependent kinase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets